KURA ONCOLOGY INC (KURA) Fundamental Analysis & Valuation

NASDAQ:KURA • US50127T1097

Current stock price

8.07 USD
-0.25 (-3%)
At close:
8.23 USD
+0.16 (+1.98%)
After Hours:

This KURA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KURA Profitability Analysis

1.1 Basic Checks

  • KURA had negative earnings in the past year.
  • KURA had a negative operating cash flow in the past year.
  • In the past 5 years KURA always reported negative net income.
  • KURA had negative operating cash flow in 4 of the past 5 years.
KURA Yearly Net Income VS EBIT VS OCF VS FCFKURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -37.74%, KURA is in line with its industry, outperforming 59.54% of the companies in the same industry.
  • With a Return On Equity value of -160.03%, KURA is not doing good in the industry: 65.13% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -37.74%
ROE -160.03%
ROIC N/A
ROA(3y)-31.54%
ROA(5y)-29.76%
ROE(3y)-80.17%
ROE(5y)-59.72%
ROIC(3y)N/A
ROIC(5y)N/A
KURA Yearly ROA, ROE, ROICKURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 99.92%, KURA belongs to the best of the industry, outperforming 98.65% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for KURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KURA Yearly Profit, Operating, Gross MarginsKURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. KURA Health Analysis

2.1 Basic Checks

  • KURA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for KURA has been increased compared to 1 year ago.
  • Compared to 5 years ago, KURA has more shares outstanding
  • KURA has a worse debt/assets ratio than last year.
KURA Yearly Shares OutstandingKURA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
KURA Yearly Total Debt VS Total AssetsKURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • KURA has an Altman-Z score of -1.75. This is a bad value and indicates that KURA is not financially healthy and even has some risk of bankruptcy.
  • KURA has a Altman-Z score of -1.75. This is comparable to the rest of the industry: KURA outperforms 51.45% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that KURA is not too dependend on debt financing.
  • The Debt to Equity ratio of KURA (0.06) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.75
ROIC/WACCN/A
WACC9.31%
KURA Yearly LT Debt VS Equity VS FCFKURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.06 indicates that KURA has no problem at all paying its short term obligations.
  • KURA has a better Current ratio (6.06) than 63.01% of its industry peers.
  • KURA has a Quick Ratio of 6.05. This indicates that KURA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.05, KURA is doing good in the industry, outperforming 64.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.06
Quick Ratio 6.05
KURA Yearly Current Assets VS Current LiabilitesKURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. KURA Growth Analysis

3.1 Past

  • KURA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.65%.
  • The Revenue has grown by 25.24% in the past year. This is a very strong growth!
EPS 1Y (TTM)-56.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-318.18%
Revenue 1Y (TTM)25.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-67.83%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.02% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, KURA will show a very strong growth in Revenue. The Revenue will grow by 60.41% on average per year.
EPS Next Y-1.15%
EPS Next 2Y7.61%
EPS Next 3Y21.1%
EPS Next 5Y30.02%
Revenue Next Year-9.18%
Revenue Next 2Y19.83%
Revenue Next 3Y26.82%
Revenue Next 5Y60.41%

3.3 Evolution

KURA Yearly Revenue VS EstimatesKURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
KURA Yearly EPS VS EstimatesKURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. KURA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KURA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KURA Price Earnings VS Forward Price EarningsKURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KURA Per share dataKURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KURA's earnings are expected to grow with 21.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.61%
EPS Next 3Y21.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KURA Dividend Analysis

5.1 Amount

  • No dividends for KURA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KURA Fundamentals: All Metrics, Ratios and Statistics

KURA ONCOLOGY INC

NASDAQ:KURA (3/24/2026, 8:00:02 PM)

After market: 8.23 +0.16 (+1.98%)

8.07

-0.25 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)04-29
Inst Owners98.55%
Inst Owner Change2.45%
Ins Owners2.38%
Ins Owner Change13.13%
Market Cap712.82M
Revenue(TTM)67.48M
Net Income(TTM)-278.67M
Analysts82.86
Price Target32.33 (300.62%)
Short Float %17.26%
Short Ratio9.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.92%
Min EPS beat(2)-86.01%
Max EPS beat(2)2.17%
EPS beat(4)1
Avg EPS beat(4)-52.41%
Min EPS beat(4)-86.01%
Max EPS beat(4)2.17%
EPS beat(8)4
Avg EPS beat(8)-17.42%
EPS beat(12)8
Avg EPS beat(12)-9.28%
EPS beat(16)12
Avg EPS beat(16)-4.98%
Revenue beat(2)0
Avg Revenue beat(2)-64.04%
Min Revenue beat(2)-77.38%
Max Revenue beat(2)-50.69%
Revenue beat(4)1
Avg Revenue beat(4)-43.97%
Min Revenue beat(4)-77.38%
Max Revenue beat(4)11.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.6%
PT rev (3m)-3.94%
EPS NQ rev (1m)-337.56%
EPS NQ rev (3m)-450.34%
EPS NY rev (1m)-3.09%
EPS NY rev (3m)-28.49%
Revenue NQ rev (1m)-78.86%
Revenue NQ rev (3m)-79.81%
Revenue NY rev (1m)-32.69%
Revenue NY rev (3m)-49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.56
P/FCF N/A
P/OCF N/A
P/B 4.09
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-3.22
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.76
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.74%
ROE -160.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.92%
FCFM N/A
ROA(3y)-31.54%
ROA(5y)-29.76%
ROE(3y)-80.17%
ROE(5y)-59.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 643.22%
Cap/Sales 9.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.06
Quick Ratio 6.05
Altman-Z -1.75
F-Score2
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)239.56%
Cap/Depr(5y)201.38%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-318.18%
EPS Next Y-1.15%
EPS Next 2Y7.61%
EPS Next 3Y21.1%
EPS Next 5Y30.02%
Revenue 1Y (TTM)25.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-67.83%
Revenue Next Year-9.18%
Revenue Next 2Y19.83%
Revenue Next 3Y26.82%
Revenue Next 5Y60.41%
EBIT growth 1Y-57.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.36%
EBIT Next 3Y-7.52%
EBIT Next 5Y4.54%
FCF growth 1Y-152.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.69%
OCF growth 3YN/A
OCF growth 5YN/A

KURA ONCOLOGY INC / KURA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KURA.


What is the valuation status of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a valuation rating of 1 / 10 to KURA ONCOLOGY INC (KURA). This can be considered as Overvalued.


Can you provide the profitability details for KURA ONCOLOGY INC?

KURA ONCOLOGY INC (KURA) has a profitability rating of 1 / 10.


How financially healthy is KURA ONCOLOGY INC?

The financial health rating of KURA ONCOLOGY INC (KURA) is 4 / 10.